Business
LIVE: The Top 10 Future Tech Trends From 5 Top Venture Capitalists
Yesterday - Forbes
The only thing people in Silicon Valley like to do more than talk about the future of tech is to invent it. Tonight they settled for the second-best thing, in the form of the popular Top 10 Tech Trends dinner
Bits Blog: Tax Protest in Britain Focuses on Google
Yesterday - New York Times Business
A group of drama students is organizing a Google Free Day, highlighting what they say is the minimal share of its revenue that the search giant pays in taxes.
Twitter Lets Brands Find Viewers of Their TV Ads
Yesterday - New York Times Business
A new product, Twitter Amplify, will help brands match advertisements with Twitter commentary by viewers.
DealBook: Bank’s Lobbyists Help in Drafting Financial Bills
Yesterday - New York Times Business
Citigroup’s ideas were reflected in more than 70 lines of one 85-line bill.
California Puts Tentative Price on Health Policies Under New Law
Yesterday - New York Times Business
Thirteen insurers had been chosen to sell policies through the insurance marketplace — or exchange — being created under the law.
Swiss Banking Secrecy Under Pressure From Europe
Yesterday - New York Times Business
European Union officials, having won concessions from bloc members Luxembourg and Austria over banking rules, are expected to turn their focus to Switzerland.
DealBook: 4 SAC Executives Subpoenaed in Insider Trading Inquiry
Yesterday - New York Times Business
The four executives were ordered to testify before a grand jury investigating actions at the hedge fund.
DealBook: Some in Congress Grow More Wary of Selling Sprint to SoftBank of Japan
Yesterday - New York Times Business
National security concerns are rooted in SoftBank’s relationship with Chinese telecommunications equipment manufacturers.
Abruptly, P.&G. Chief Ends Career of 33 Years
Yesterday - New York Times Business
The hedge fund manager William Ackman had criticized Robert A. McDonald, the chief, for the company’s poor stock performance.
Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
Yesterday - Forbes
This morning, I published a guest post from Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, alleging that the most likely rationale for an upcoming panel meeting being held by the Food and Drug Administration was to make some FDA leaders less accountable for the scandals that surrounded the diabetes dru...
Copyright © 2013 Shyftr, All Rights Reserved
